nodes	percent_of_prediction	percent_of_DWPC	metapath
Methysergide—Bromocriptine—type 2 diabetes mellitus	0.407	1	CrCtD
Methysergide—HTR2C—type 2 diabetes mellitus	0.095	1	CbGaD
Methysergide—Methylergometrine—Bromocriptine—type 2 diabetes mellitus	0.0831	0.347	CrCrCtD
Methysergide—Ergonovine—Bromocriptine—type 2 diabetes mellitus	0.0831	0.347	CrCrCtD
Methysergide—Ergotamine—Bromocriptine—type 2 diabetes mellitus	0.0734	0.307	CrCrCtD
Methysergide—HTR7—Bromocriptine—type 2 diabetes mellitus	0.0274	0.176	CbGbCtD
Methysergide—HTR6—Bromocriptine—type 2 diabetes mellitus	0.024	0.154	CbGbCtD
Methysergide—HTR1D—Bromocriptine—type 2 diabetes mellitus	0.0219	0.141	CbGbCtD
Methysergide—HTR2B—Bromocriptine—type 2 diabetes mellitus	0.0215	0.138	CbGbCtD
Methysergide—HTR1B—Bromocriptine—type 2 diabetes mellitus	0.021	0.135	CbGbCtD
Methysergide—HTR2C—Bromocriptine—type 2 diabetes mellitus	0.014	0.0898	CbGbCtD
Methysergide—HTR1A—Bromocriptine—type 2 diabetes mellitus	0.0132	0.0846	CbGbCtD
Methysergide—HTR2A—Bromocriptine—type 2 diabetes mellitus	0.0126	0.0809	CbGbCtD
Methysergide—HTR7—sympathetic nervous system—type 2 diabetes mellitus	0.00133	0.0976	CbGeAlD
Methysergide—HTR2A—arteriole—type 2 diabetes mellitus	0.0013	0.0955	CbGeAlD
Methysergide—HTR7—autonomic nervous system—type 2 diabetes mellitus	0.000892	0.0656	CbGeAlD
Methysergide—HTR2A—sympathetic nervous system—type 2 diabetes mellitus	0.000828	0.0608	CbGeAlD
Methysergide—HTR1B—artery—type 2 diabetes mellitus	0.000656	0.0482	CbGeAlD
Methysergide—HTR7—peripheral nervous system—type 2 diabetes mellitus	0.000644	0.0473	CbGeAlD
Methysergide—HTR1D—artery—type 2 diabetes mellitus	0.000635	0.0467	CbGeAlD
Methysergide—HTR2A—autonomic nervous system—type 2 diabetes mellitus	0.000556	0.0409	CbGeAlD
Methysergide—HTR2A—hindlimb—type 2 diabetes mellitus	0.000515	0.0378	CbGeAlD
Methysergide—HTR7—artery—type 2 diabetes mellitus	0.000506	0.0372	CbGeAlD
Methysergide—HTR7—nerve—type 2 diabetes mellitus	0.000502	0.0369	CbGeAlD
Methysergide—HTR7—endothelium—type 2 diabetes mellitus	0.000427	0.0314	CbGeAlD
Methysergide—HTR2A—peripheral nervous system—type 2 diabetes mellitus	0.000401	0.0295	CbGeAlD
Methysergide—HTR2A—artery—type 2 diabetes mellitus	0.000316	0.0232	CbGeAlD
Methysergide—HTR2A—nerve—type 2 diabetes mellitus	0.000313	0.023	CbGeAlD
Methysergide—SIGMAR1—islet of Langerhans—type 2 diabetes mellitus	0.000285	0.0209	CbGeAlD
Methysergide—HTR2A—endothelium—type 2 diabetes mellitus	0.000267	0.0196	CbGeAlD
Methysergide—SIGMAR1—nephron tubule—type 2 diabetes mellitus	0.000229	0.0168	CbGeAlD
Methysergide—HTR1B—cardiovascular system—type 2 diabetes mellitus	0.000228	0.0168	CbGeAlD
Methysergide—HTR1D—cardiovascular system—type 2 diabetes mellitus	0.000221	0.0162	CbGeAlD
Methysergide—HTR1D—kidney—type 2 diabetes mellitus	0.000216	0.0159	CbGeAlD
Methysergide—HTR2B—cardiovascular system—type 2 diabetes mellitus	0.000205	0.0151	CbGeAlD
Methysergide—SIGMAR1—pancreas—type 2 diabetes mellitus	0.0002	0.0147	CbGeAlD
Methysergide—SIGMAR1—cortex of kidney—type 2 diabetes mellitus	0.000196	0.0144	CbGeAlD
Methysergide—HTR2B—cortex of kidney—type 2 diabetes mellitus	0.000196	0.0144	CbGeAlD
Methysergide—HTR1A—cardiovascular system—type 2 diabetes mellitus	0.000184	0.0135	CbGeAlD
Methysergide—SIGMAR1—adipose tissue—type 2 diabetes mellitus	0.000181	0.0133	CbGeAlD
Methysergide—Ergonovine—HTR2C—type 2 diabetes mellitus	0.000181	0.125	CrCbGaD
Methysergide—HTR2B—adipose tissue—type 2 diabetes mellitus	0.000181	0.0133	CbGeAlD
Methysergide—HTR7—cardiovascular system—type 2 diabetes mellitus	0.000176	0.0129	CbGeAlD
Methysergide—HTR7—kidney—type 2 diabetes mellitus	0.000172	0.0126	CbGeAlD
Methysergide—Methylergometrine—HTR2C—type 2 diabetes mellitus	0.000158	0.109	CrCbGaD
Methysergide—HTR2A—retina—type 2 diabetes mellitus	0.00013	0.00953	CbGeAlD
Methysergide—SIGMAR1—liver—type 2 diabetes mellitus	0.000127	0.00935	CbGeAlD
Methysergide—Lisuride—ADRA2A—type 2 diabetes mellitus	0.000115	0.0794	CrCbGaD
Methysergide—Ergotamine—ADRA2A—type 2 diabetes mellitus	0.000111	0.0763	CrCbGaD
Methysergide—HTR2A—cardiovascular system—type 2 diabetes mellitus	0.00011	0.00806	CbGeAlD
Methysergide—HTR7—liver—type 2 diabetes mellitus	0.000109	0.00799	CbGeAlD
Methysergide—HTR2A—kidney—type 2 diabetes mellitus	0.000107	0.00788	CbGeAlD
Methysergide—Bromocriptine—ADRA2A—type 2 diabetes mellitus	0.000107	0.0735	CrCbGaD
Methysergide—Lisuride—HTR2C—type 2 diabetes mellitus	0.000106	0.0731	CrCbGaD
Methysergide—Ergotamine—HTR2C—type 2 diabetes mellitus	0.000102	0.0702	CrCbGaD
Methysergide—Bromocriptine—HTR2C—type 2 diabetes mellitus	9.85e-05	0.0677	CrCbGaD
Methysergide—Ergonovine—CYP3A4—type 2 diabetes mellitus	9.06e-05	0.0623	CrCbGaD
Methysergide—Methylergometrine—CYP3A4—type 2 diabetes mellitus	7.91e-05	0.0544	CrCbGaD
Methysergide—Ergotamine—CYP1A2—type 2 diabetes mellitus	7.7e-05	0.053	CrCbGaD
Methysergide—Bromocriptine—CYP1A2—type 2 diabetes mellitus	7.43e-05	0.0511	CrCbGaD
Methysergide—Myalgia—Gliclazide—type 2 diabetes mellitus	7.43e-05	0.00137	CcSEcCtD
Methysergide—Chest pain—Gliclazide—type 2 diabetes mellitus	7.43e-05	0.00137	CcSEcCtD
Methysergide—Arthralgia—Gliclazide—type 2 diabetes mellitus	7.43e-05	0.00137	CcSEcCtD
Methysergide—Rash—Rosiglitazone—type 2 diabetes mellitus	7.42e-05	0.00136	CcSEcCtD
Methysergide—Constipation—Bromocriptine—type 2 diabetes mellitus	7.42e-05	0.00136	CcSEcCtD
Methysergide—Dermatitis—Rosiglitazone—type 2 diabetes mellitus	7.42e-05	0.00136	CcSEcCtD
Methysergide—Nausea—Repaglinide—type 2 diabetes mellitus	7.4e-05	0.00136	CcSEcCtD
Methysergide—Asthenia—Glipizide—type 2 diabetes mellitus	7.39e-05	0.00136	CcSEcCtD
Methysergide—Ill-defined disorder—Orlistat—type 2 diabetes mellitus	7.35e-05	0.00135	CcSEcCtD
Methysergide—Flushing—Irbesartan—type 2 diabetes mellitus	7.35e-05	0.00135	CcSEcCtD
Methysergide—Discomfort—Gliclazide—type 2 diabetes mellitus	7.34e-05	0.00135	CcSEcCtD
Methysergide—Weight increased—Ramipril—type 2 diabetes mellitus	7.26e-05	0.00133	CcSEcCtD
Methysergide—Musculoskeletal discomfort—Glyburide—type 2 diabetes mellitus	7.23e-05	0.00133	CcSEcCtD
Methysergide—Feeling abnormal—Bromocriptine—type 2 diabetes mellitus	7.15e-05	0.00131	CcSEcCtD
Methysergide—Malaise—Orlistat—type 2 diabetes mellitus	7.14e-05	0.00131	CcSEcCtD
Methysergide—Paraesthesia—Glyburide—type 2 diabetes mellitus	7.12e-05	0.00131	CcSEcCtD
Methysergide—Gastrointestinal pain—Bromocriptine—type 2 diabetes mellitus	7.09e-05	0.0013	CcSEcCtD
Methysergide—Asthenia—Pioglitazone—type 2 diabetes mellitus	7.08e-05	0.0013	CcSEcCtD
Methysergide—Dyspnoea—Glyburide—type 2 diabetes mellitus	7.07e-05	0.0013	CcSEcCtD
Methysergide—Diarrhoea—Glipizide—type 2 diabetes mellitus	7.05e-05	0.0013	CcSEcCtD
Methysergide—Nausea—Rosiglitazone—type 2 diabetes mellitus	6.99e-05	0.00129	CcSEcCtD
Methysergide—Dyspepsia—Glyburide—type 2 diabetes mellitus	6.98e-05	0.00128	CcSEcCtD
Methysergide—Thrombocytopenia—Gliclazide—type 2 diabetes mellitus	6.97e-05	0.00128	CcSEcCtD
Methysergide—Tachycardia—Gliclazide—type 2 diabetes mellitus	6.95e-05	0.00128	CcSEcCtD
Methysergide—Flushing—Losartan—type 2 diabetes mellitus	6.91e-05	0.00127	CcSEcCtD
Methysergide—Asthenia—Glimepiride—type 2 diabetes mellitus	6.9e-05	0.00127	CcSEcCtD
Methysergide—Asthenia—Sitagliptin—type 2 diabetes mellitus	6.88e-05	0.00126	CcSEcCtD
Methysergide—Convulsion—Orlistat—type 2 diabetes mellitus	6.86e-05	0.00126	CcSEcCtD
Methysergide—Abdominal pain—Bromocriptine—type 2 diabetes mellitus	6.86e-05	0.00126	CcSEcCtD
Methysergide—Body temperature increased—Bromocriptine—type 2 diabetes mellitus	6.86e-05	0.00126	CcSEcCtD
Methysergide—Gastrointestinal disorder—Glyburide—type 2 diabetes mellitus	6.85e-05	0.00126	CcSEcCtD
Methysergide—Arthralgia—Valsartan—type 2 diabetes mellitus	6.83e-05	0.00125	CcSEcCtD
Methysergide—Chest pain—Valsartan—type 2 diabetes mellitus	6.83e-05	0.00125	CcSEcCtD
Methysergide—Myalgia—Valsartan—type 2 diabetes mellitus	6.83e-05	0.00125	CcSEcCtD
Methysergide—Dizziness—Glipizide—type 2 diabetes mellitus	6.81e-05	0.00125	CcSEcCtD
Methysergide—HTR2A—liver—type 2 diabetes mellitus	6.78e-05	0.00498	CbGeAlD
Methysergide—Ill-defined disorder—Metformin—type 2 diabetes mellitus	6.77e-05	0.00125	CcSEcCtD
Methysergide—Diarrhoea—Pioglitazone—type 2 diabetes mellitus	6.75e-05	0.00124	CcSEcCtD
Methysergide—Myalgia—Orlistat—type 2 diabetes mellitus	6.74e-05	0.00124	CcSEcCtD
Methysergide—Chest pain—Orlistat—type 2 diabetes mellitus	6.74e-05	0.00124	CcSEcCtD
Methysergide—Discomfort—Orlistat—type 2 diabetes mellitus	6.66e-05	0.00123	CcSEcCtD
Methysergide—Malaise—Metformin—type 2 diabetes mellitus	6.58e-05	0.00121	CcSEcCtD
Methysergide—Alopecia—Losartan—type 2 diabetes mellitus	6.58e-05	0.00121	CcSEcCtD
Methysergide—Diarrhoea—Glimepiride—type 2 diabetes mellitus	6.58e-05	0.00121	CcSEcCtD
Methysergide—Diarrhoea—Sitagliptin—type 2 diabetes mellitus	6.56e-05	0.00121	CcSEcCtD
Methysergide—Vomiting—Glipizide—type 2 diabetes mellitus	6.55e-05	0.0012	CcSEcCtD
Methysergide—Oedema—Valsartan—type 2 diabetes mellitus	6.54e-05	0.0012	CcSEcCtD
Methysergide—Feeling abnormal—Glyburide—type 2 diabetes mellitus	6.54e-05	0.0012	CcSEcCtD
Methysergide—Dizziness—Pioglitazone—type 2 diabetes mellitus	6.53e-05	0.0012	CcSEcCtD
Methysergide—Rash—Glipizide—type 2 diabetes mellitus	6.5e-05	0.00119	CcSEcCtD
Methysergide—Dermatitis—Glipizide—type 2 diabetes mellitus	6.49e-05	0.00119	CcSEcCtD
Methysergide—Musculoskeletal discomfort—Gliclazide—type 2 diabetes mellitus	6.49e-05	0.00119	CcSEcCtD
Methysergide—Gastrointestinal pain—Glyburide—type 2 diabetes mellitus	6.49e-05	0.00119	CcSEcCtD
Methysergide—Oedema—Orlistat—type 2 diabetes mellitus	6.47e-05	0.00119	CcSEcCtD
Methysergide—Insomnia—Gliclazide—type 2 diabetes mellitus	6.44e-05	0.00118	CcSEcCtD
Methysergide—Thrombocytopenia—Valsartan—type 2 diabetes mellitus	6.41e-05	0.00118	CcSEcCtD
Methysergide—Paraesthesia—Gliclazide—type 2 diabetes mellitus	6.39e-05	0.00118	CcSEcCtD
Methysergide—Ill-defined disorder—Irbesartan—type 2 diabetes mellitus	6.39e-05	0.00118	CcSEcCtD
Methysergide—Dizziness—Glimepiride—type 2 diabetes mellitus	6.36e-05	0.00117	CcSEcCtD
Methysergide—Dyspnoea—Gliclazide—type 2 diabetes mellitus	6.35e-05	0.00117	CcSEcCtD
Methysergide—Dizziness—Sitagliptin—type 2 diabetes mellitus	6.34e-05	0.00117	CcSEcCtD
Methysergide—Somnolence—Gliclazide—type 2 diabetes mellitus	6.33e-05	0.00116	CcSEcCtD
Methysergide—Oedema peripheral—Ramipril—type 2 diabetes mellitus	6.29e-05	0.00116	CcSEcCtD
Methysergide—Back pain—Losartan—type 2 diabetes mellitus	6.27e-05	0.00115	CcSEcCtD
Methysergide—Abdominal pain—Glyburide—type 2 diabetes mellitus	6.27e-05	0.00115	CcSEcCtD
Methysergide—Dyspepsia—Gliclazide—type 2 diabetes mellitus	6.27e-05	0.00115	CcSEcCtD
Methysergide—Asthenia—Bromocriptine—type 2 diabetes mellitus	6.22e-05	0.00114	CcSEcCtD
Methysergide—Myalgia—Metformin—type 2 diabetes mellitus	6.22e-05	0.00114	CcSEcCtD
Methysergide—Chest pain—Metformin—type 2 diabetes mellitus	6.22e-05	0.00114	CcSEcCtD
Methysergide—Malaise—Irbesartan—type 2 diabetes mellitus	6.21e-05	0.00114	CcSEcCtD
Methysergide—Gastrointestinal disorder—Gliclazide—type 2 diabetes mellitus	6.15e-05	0.00113	CcSEcCtD
Methysergide—Discomfort—Metformin—type 2 diabetes mellitus	6.14e-05	0.00113	CcSEcCtD
Methysergide—Fatigue—Gliclazide—type 2 diabetes mellitus	6.14e-05	0.00113	CcSEcCtD
Methysergide—Nausea—Glipizide—type 2 diabetes mellitus	6.12e-05	0.00113	CcSEcCtD
Methysergide—Vomiting—Glimepiride—type 2 diabetes mellitus	6.11e-05	0.00112	CcSEcCtD
Methysergide—Vomiting—Sitagliptin—type 2 diabetes mellitus	6.1e-05	0.00112	CcSEcCtD
Methysergide—Constipation—Gliclazide—type 2 diabetes mellitus	6.09e-05	0.00112	CcSEcCtD
Methysergide—Pain—Gliclazide—type 2 diabetes mellitus	6.09e-05	0.00112	CcSEcCtD
Methysergide—Rash—Glimepiride—type 2 diabetes mellitus	6.06e-05	0.00111	CcSEcCtD
Methysergide—Dermatitis—Glimepiride—type 2 diabetes mellitus	6.06e-05	0.00111	CcSEcCtD
Methysergide—Rash—Sitagliptin—type 2 diabetes mellitus	6.04e-05	0.00111	CcSEcCtD
Methysergide—Dermatitis—Sitagliptin—type 2 diabetes mellitus	6.04e-05	0.00111	CcSEcCtD
Methysergide—Ill-defined disorder—Losartan—type 2 diabetes mellitus	6.02e-05	0.00111	CcSEcCtD
Methysergide—Musculoskeletal discomfort—Valsartan—type 2 diabetes mellitus	5.96e-05	0.0011	CcSEcCtD
Methysergide—Oedema—Metformin—type 2 diabetes mellitus	5.96e-05	0.0011	CcSEcCtD
Methysergide—Diarrhoea—Bromocriptine—type 2 diabetes mellitus	5.94e-05	0.00109	CcSEcCtD
Methysergide—Flushing—Ramipril—type 2 diabetes mellitus	5.93e-05	0.00109	CcSEcCtD
Methysergide—Insomnia—Valsartan—type 2 diabetes mellitus	5.92e-05	0.00109	CcSEcCtD
Methysergide—Musculoskeletal discomfort—Orlistat—type 2 diabetes mellitus	5.89e-05	0.00108	CcSEcCtD
Methysergide—Paraesthesia—Valsartan—type 2 diabetes mellitus	5.88e-05	0.00108	CcSEcCtD
Methysergide—Feeling abnormal—Gliclazide—type 2 diabetes mellitus	5.87e-05	0.00108	CcSEcCtD
Methysergide—Chest pain—Irbesartan—type 2 diabetes mellitus	5.87e-05	0.00108	CcSEcCtD
Methysergide—Arthralgia—Irbesartan—type 2 diabetes mellitus	5.87e-05	0.00108	CcSEcCtD
Methysergide—Myalgia—Irbesartan—type 2 diabetes mellitus	5.87e-05	0.00108	CcSEcCtD
Methysergide—Insomnia—Orlistat—type 2 diabetes mellitus	5.85e-05	0.00108	CcSEcCtD
Methysergide—Malaise—Losartan—type 2 diabetes mellitus	5.85e-05	0.00107	CcSEcCtD
Methysergide—Thrombocytopenia—Metformin—type 2 diabetes mellitus	5.83e-05	0.00107	CcSEcCtD
Methysergide—Dyspnoea—Valsartan—type 2 diabetes mellitus	5.83e-05	0.00107	CcSEcCtD
Methysergide—Gastrointestinal pain—Gliclazide—type 2 diabetes mellitus	5.82e-05	0.00107	CcSEcCtD
Methysergide—Somnolence—Valsartan—type 2 diabetes mellitus	5.82e-05	0.00107	CcSEcCtD
Methysergide—Paraesthesia—Orlistat—type 2 diabetes mellitus	5.81e-05	0.00107	CcSEcCtD
Methysergide—Discomfort—Irbesartan—type 2 diabetes mellitus	5.8e-05	0.00107	CcSEcCtD
Methysergide—Dyspepsia—Valsartan—type 2 diabetes mellitus	5.76e-05	0.00106	CcSEcCtD
Methysergide—Dizziness—Bromocriptine—type 2 diabetes mellitus	5.74e-05	0.00105	CcSEcCtD
Methysergide—Nausea—Glimepiride—type 2 diabetes mellitus	5.71e-05	0.00105	CcSEcCtD
Methysergide—Nausea—Sitagliptin—type 2 diabetes mellitus	5.69e-05	0.00105	CcSEcCtD
Methysergide—Dyspepsia—Orlistat—type 2 diabetes mellitus	5.69e-05	0.00105	CcSEcCtD
Methysergide—Asthenia—Glyburide—type 2 diabetes mellitus	5.69e-05	0.00105	CcSEcCtD
Methysergide—Gastrointestinal disorder—Valsartan—type 2 diabetes mellitus	5.65e-05	0.00104	CcSEcCtD
Methysergide—Alopecia—Ramipril—type 2 diabetes mellitus	5.64e-05	0.00104	CcSEcCtD
Methysergide—Fatigue—Valsartan—type 2 diabetes mellitus	5.64e-05	0.00104	CcSEcCtD
Methysergide—Abdominal pain—Gliclazide—type 2 diabetes mellitus	5.63e-05	0.00103	CcSEcCtD
Methysergide—Body temperature increased—Gliclazide—type 2 diabetes mellitus	5.63e-05	0.00103	CcSEcCtD
Methysergide—Oedema—Irbesartan—type 2 diabetes mellitus	5.62e-05	0.00103	CcSEcCtD
Methysergide—Constipation—Valsartan—type 2 diabetes mellitus	5.6e-05	0.00103	CcSEcCtD
Methysergide—Gastrointestinal disorder—Orlistat—type 2 diabetes mellitus	5.58e-05	0.00103	CcSEcCtD
Methysergide—Fatigue—Orlistat—type 2 diabetes mellitus	5.57e-05	0.00102	CcSEcCtD
Methysergide—Pain—Orlistat—type 2 diabetes mellitus	5.53e-05	0.00102	CcSEcCtD
Methysergide—Myalgia—Losartan—type 2 diabetes mellitus	5.52e-05	0.00101	CcSEcCtD
Methysergide—Chest pain—Losartan—type 2 diabetes mellitus	5.52e-05	0.00101	CcSEcCtD
Methysergide—Arthralgia—Losartan—type 2 diabetes mellitus	5.52e-05	0.00101	CcSEcCtD
Methysergide—Vomiting—Bromocriptine—type 2 diabetes mellitus	5.52e-05	0.00101	CcSEcCtD
Methysergide—Thrombocytopenia—Irbesartan—type 2 diabetes mellitus	5.51e-05	0.00101	CcSEcCtD
Methysergide—Tachycardia—Irbesartan—type 2 diabetes mellitus	5.49e-05	0.00101	CcSEcCtD
Methysergide—Rash—Bromocriptine—type 2 diabetes mellitus	5.47e-05	0.00101	CcSEcCtD
Methysergide—Dermatitis—Bromocriptine—type 2 diabetes mellitus	5.46e-05	0.001	CcSEcCtD
Methysergide—Discomfort—Losartan—type 2 diabetes mellitus	5.45e-05	0.001	CcSEcCtD
Methysergide—Musculoskeletal discomfort—Metformin—type 2 diabetes mellitus	5.43e-05	0.000998	CcSEcCtD
Methysergide—Diarrhoea—Glyburide—type 2 diabetes mellitus	5.43e-05	0.000998	CcSEcCtD
Methysergide—Gastrointestinal pain—Valsartan—type 2 diabetes mellitus	5.35e-05	0.000984	CcSEcCtD
Methysergide—Paraesthesia—Metformin—type 2 diabetes mellitus	5.35e-05	0.000984	CcSEcCtD
Methysergide—Feeling abnormal—Orlistat—type 2 diabetes mellitus	5.33e-05	0.000979	CcSEcCtD
Methysergide—Dyspnoea—Metformin—type 2 diabetes mellitus	5.31e-05	0.000977	CcSEcCtD
Methysergide—Lisuride—CYP3A4—type 2 diabetes mellitus	5.31e-05	0.0365	CrCbGaD
Methysergide—Somnolence—Metformin—type 2 diabetes mellitus	5.3e-05	0.000974	CcSEcCtD
Methysergide—Oedema—Losartan—type 2 diabetes mellitus	5.29e-05	0.000973	CcSEcCtD
Methysergide—Gastrointestinal pain—Orlistat—type 2 diabetes mellitus	5.29e-05	0.000972	CcSEcCtD
Methysergide—Dyspepsia—Metformin—type 2 diabetes mellitus	5.24e-05	0.000964	CcSEcCtD
Methysergide—Thrombocytopenia—Losartan—type 2 diabetes mellitus	5.18e-05	0.000953	CcSEcCtD
Methysergide—Abdominal pain—Valsartan—type 2 diabetes mellitus	5.17e-05	0.000951	CcSEcCtD
Methysergide—Tachycardia—Losartan—type 2 diabetes mellitus	5.16e-05	0.000949	CcSEcCtD
Methysergide—Ill-defined disorder—Ramipril—type 2 diabetes mellitus	5.16e-05	0.000948	CcSEcCtD
Methysergide—Nausea—Bromocriptine—type 2 diabetes mellitus	5.15e-05	0.000947	CcSEcCtD
Methysergide—Gastrointestinal disorder—Metformin—type 2 diabetes mellitus	5.14e-05	0.000946	CcSEcCtD
Methysergide—Fatigue—Metformin—type 2 diabetes mellitus	5.14e-05	0.000944	CcSEcCtD
Methysergide—Musculoskeletal discomfort—Irbesartan—type 2 diabetes mellitus	5.12e-05	0.000942	CcSEcCtD
Methysergide—Abdominal pain—Orlistat—type 2 diabetes mellitus	5.11e-05	0.00094	CcSEcCtD
Methysergide—Body temperature increased—Orlistat—type 2 diabetes mellitus	5.11e-05	0.00094	CcSEcCtD
Methysergide—Asthenia—Gliclazide—type 2 diabetes mellitus	5.11e-05	0.000939	CcSEcCtD
Methysergide—Ergotamine—CYP3A4—type 2 diabetes mellitus	5.1e-05	0.0351	CrCbGaD
Methysergide—Constipation—Metformin—type 2 diabetes mellitus	5.1e-05	0.000937	CcSEcCtD
Methysergide—Paraesthesia—Irbesartan—type 2 diabetes mellitus	5.05e-05	0.000928	CcSEcCtD
Methysergide—Vomiting—Glyburide—type 2 diabetes mellitus	5.04e-05	0.000927	CcSEcCtD
Methysergide—Malaise—Ramipril—type 2 diabetes mellitus	5.01e-05	0.000922	CcSEcCtD
Methysergide—Dyspnoea—Irbesartan—type 2 diabetes mellitus	5.01e-05	0.000922	CcSEcCtD
Methysergide—Rash—Glyburide—type 2 diabetes mellitus	5e-05	0.000919	CcSEcCtD
Methysergide—Somnolence—Irbesartan—type 2 diabetes mellitus	5e-05	0.000919	CcSEcCtD
Methysergide—Dermatitis—Glyburide—type 2 diabetes mellitus	5e-05	0.000918	CcSEcCtD
Methysergide—Dyspepsia—Irbesartan—type 2 diabetes mellitus	4.95e-05	0.00091	CcSEcCtD
Methysergide—Bromocriptine—CYP3A4—type 2 diabetes mellitus	4.92e-05	0.0338	CrCbGaD
Methysergide—Feeling abnormal—Metformin—type 2 diabetes mellitus	4.91e-05	0.000903	CcSEcCtD
Methysergide—Diarrhoea—Gliclazide—type 2 diabetes mellitus	4.87e-05	0.000896	CcSEcCtD
Methysergide—Gastrointestinal pain—Metformin—type 2 diabetes mellitus	4.87e-05	0.000896	CcSEcCtD
Methysergide—Gastrointestinal disorder—Irbesartan—type 2 diabetes mellitus	4.85e-05	0.000892	CcSEcCtD
Methysergide—Fatigue—Irbesartan—type 2 diabetes mellitus	4.85e-05	0.000891	CcSEcCtD
Methysergide—Musculoskeletal discomfort—Losartan—type 2 diabetes mellitus	4.82e-05	0.000886	CcSEcCtD
Methysergide—Convulsion—Ramipril—type 2 diabetes mellitus	4.82e-05	0.000886	CcSEcCtD
Methysergide—Constipation—Irbesartan—type 2 diabetes mellitus	4.81e-05	0.000884	CcSEcCtD
Methysergide—Pain—Irbesartan—type 2 diabetes mellitus	4.81e-05	0.000884	CcSEcCtD
Methysergide—Insomnia—Losartan—type 2 diabetes mellitus	4.79e-05	0.00088	CcSEcCtD
Methysergide—Paraesthesia—Losartan—type 2 diabetes mellitus	4.75e-05	0.000874	CcSEcCtD
Methysergide—Myalgia—Ramipril—type 2 diabetes mellitus	4.73e-05	0.00087	CcSEcCtD
Methysergide—Chest pain—Ramipril—type 2 diabetes mellitus	4.73e-05	0.00087	CcSEcCtD
Methysergide—Arthralgia—Ramipril—type 2 diabetes mellitus	4.73e-05	0.00087	CcSEcCtD
Methysergide—Dyspnoea—Losartan—type 2 diabetes mellitus	4.72e-05	0.000867	CcSEcCtD
Methysergide—Nausea—Glyburide—type 2 diabetes mellitus	4.71e-05	0.000866	CcSEcCtD
Methysergide—Abdominal pain—Metformin—type 2 diabetes mellitus	4.71e-05	0.000866	CcSEcCtD
Methysergide—Dizziness—Gliclazide—type 2 diabetes mellitus	4.71e-05	0.000866	CcSEcCtD
Methysergide—Somnolence—Losartan—type 2 diabetes mellitus	4.7e-05	0.000865	CcSEcCtD
Methysergide—Asthenia—Valsartan—type 2 diabetes mellitus	4.69e-05	0.000863	CcSEcCtD
Methysergide—Discomfort—Ramipril—type 2 diabetes mellitus	4.68e-05	0.00086	CcSEcCtD
Methysergide—Dyspepsia—Losartan—type 2 diabetes mellitus	4.66e-05	0.000856	CcSEcCtD
Methysergide—Asthenia—Orlistat—type 2 diabetes mellitus	4.64e-05	0.000853	CcSEcCtD
Methysergide—Feeling abnormal—Irbesartan—type 2 diabetes mellitus	4.63e-05	0.000852	CcSEcCtD
Methysergide—Gastrointestinal pain—Irbesartan—type 2 diabetes mellitus	4.6e-05	0.000845	CcSEcCtD
Methysergide—Fatigue—Losartan—type 2 diabetes mellitus	4.56e-05	0.000839	CcSEcCtD
Methysergide—Oedema—Ramipril—type 2 diabetes mellitus	4.54e-05	0.000834	CcSEcCtD
Methysergide—Vomiting—Gliclazide—type 2 diabetes mellitus	4.53e-05	0.000832	CcSEcCtD
Methysergide—Pain—Losartan—type 2 diabetes mellitus	4.53e-05	0.000832	CcSEcCtD
Methysergide—Constipation—Losartan—type 2 diabetes mellitus	4.53e-05	0.000832	CcSEcCtD
Methysergide—Rash—Gliclazide—type 2 diabetes mellitus	4.49e-05	0.000826	CcSEcCtD
Methysergide—Dermatitis—Gliclazide—type 2 diabetes mellitus	4.49e-05	0.000825	CcSEcCtD
Methysergide—Diarrhoea—Valsartan—type 2 diabetes mellitus	4.48e-05	0.000823	CcSEcCtD
Methysergide—Abdominal pain—Irbesartan—type 2 diabetes mellitus	4.44e-05	0.000817	CcSEcCtD
Methysergide—Body temperature increased—Irbesartan—type 2 diabetes mellitus	4.44e-05	0.000817	CcSEcCtD
Methysergide—Thrombocytopenia—Ramipril—type 2 diabetes mellitus	4.44e-05	0.000817	CcSEcCtD
Methysergide—Tachycardia—Ramipril—type 2 diabetes mellitus	4.43e-05	0.000814	CcSEcCtD
Methysergide—Diarrhoea—Orlistat—type 2 diabetes mellitus	4.42e-05	0.000813	CcSEcCtD
Methysergide—Feeling abnormal—Losartan—type 2 diabetes mellitus	4.36e-05	0.000802	CcSEcCtD
Methysergide—Gastrointestinal pain—Losartan—type 2 diabetes mellitus	4.33e-05	0.000796	CcSEcCtD
Methysergide—Dizziness—Valsartan—type 2 diabetes mellitus	4.33e-05	0.000795	CcSEcCtD
Methysergide—Dizziness—Orlistat—type 2 diabetes mellitus	4.28e-05	0.000786	CcSEcCtD
Methysergide—Asthenia—Metformin—type 2 diabetes mellitus	4.27e-05	0.000786	CcSEcCtD
Methysergide—Nausea—Gliclazide—type 2 diabetes mellitus	4.23e-05	0.000778	CcSEcCtD
Methysergide—Abdominal pain—Losartan—type 2 diabetes mellitus	4.18e-05	0.000769	CcSEcCtD
Methysergide—Body temperature increased—Losartan—type 2 diabetes mellitus	4.18e-05	0.000769	CcSEcCtD
Methysergide—Vomiting—Valsartan—type 2 diabetes mellitus	4.16e-05	0.000765	CcSEcCtD
Methysergide—Musculoskeletal discomfort—Ramipril—type 2 diabetes mellitus	4.13e-05	0.00076	CcSEcCtD
Methysergide—Rash—Valsartan—type 2 diabetes mellitus	4.13e-05	0.000758	CcSEcCtD
Methysergide—Dermatitis—Valsartan—type 2 diabetes mellitus	4.12e-05	0.000758	CcSEcCtD
Methysergide—Vomiting—Orlistat—type 2 diabetes mellitus	4.11e-05	0.000756	CcSEcCtD
Methysergide—Insomnia—Ramipril—type 2 diabetes mellitus	4.1e-05	0.000754	CcSEcCtD
Methysergide—Diarrhoea—Metformin—type 2 diabetes mellitus	4.08e-05	0.000749	CcSEcCtD
Methysergide—Rash—Orlistat—type 2 diabetes mellitus	4.08e-05	0.000749	CcSEcCtD
Methysergide—Paraesthesia—Ramipril—type 2 diabetes mellitus	4.07e-05	0.000749	CcSEcCtD
Methysergide—Dermatitis—Orlistat—type 2 diabetes mellitus	4.07e-05	0.000749	CcSEcCtD
Methysergide—Dyspnoea—Ramipril—type 2 diabetes mellitus	4.05e-05	0.000744	CcSEcCtD
Methysergide—Asthenia—Irbesartan—type 2 diabetes mellitus	4.03e-05	0.000742	CcSEcCtD
Methysergide—Somnolence—Ramipril—type 2 diabetes mellitus	4.03e-05	0.000742	CcSEcCtD
Methysergide—Dyspepsia—Ramipril—type 2 diabetes mellitus	3.99e-05	0.000734	CcSEcCtD
Methysergide—Dizziness—Metformin—type 2 diabetes mellitus	3.94e-05	0.000724	CcSEcCtD
Methysergide—Gastrointestinal disorder—Ramipril—type 2 diabetes mellitus	3.92e-05	0.00072	CcSEcCtD
Methysergide—Fatigue—Ramipril—type 2 diabetes mellitus	3.91e-05	0.000719	CcSEcCtD
Methysergide—Nausea—Valsartan—type 2 diabetes mellitus	3.89e-05	0.000714	CcSEcCtD
Methysergide—Constipation—Ramipril—type 2 diabetes mellitus	3.88e-05	0.000713	CcSEcCtD
Methysergide—Diarrhoea—Irbesartan—type 2 diabetes mellitus	3.85e-05	0.000707	CcSEcCtD
Methysergide—Nausea—Orlistat—type 2 diabetes mellitus	3.84e-05	0.000706	CcSEcCtD
Methysergide—Asthenia—Losartan—type 2 diabetes mellitus	3.8e-05	0.000698	CcSEcCtD
Methysergide—Vomiting—Metformin—type 2 diabetes mellitus	3.79e-05	0.000696	CcSEcCtD
Methysergide—Rash—Metformin—type 2 diabetes mellitus	3.76e-05	0.000691	CcSEcCtD
Methysergide—Dermatitis—Metformin—type 2 diabetes mellitus	3.75e-05	0.00069	CcSEcCtD
Methysergide—Feeling abnormal—Ramipril—type 2 diabetes mellitus	3.74e-05	0.000687	CcSEcCtD
Methysergide—Dizziness—Irbesartan—type 2 diabetes mellitus	3.72e-05	0.000684	CcSEcCtD
Methysergide—Gastrointestinal pain—Ramipril—type 2 diabetes mellitus	3.71e-05	0.000682	CcSEcCtD
Methysergide—Diarrhoea—Losartan—type 2 diabetes mellitus	3.62e-05	0.000666	CcSEcCtD
Methysergide—Body temperature increased—Ramipril—type 2 diabetes mellitus	3.59e-05	0.000659	CcSEcCtD
Methysergide—Abdominal pain—Ramipril—type 2 diabetes mellitus	3.59e-05	0.000659	CcSEcCtD
Methysergide—Vomiting—Irbesartan—type 2 diabetes mellitus	3.58e-05	0.000657	CcSEcCtD
Methysergide—Rash—Irbesartan—type 2 diabetes mellitus	3.55e-05	0.000652	CcSEcCtD
Methysergide—Dermatitis—Irbesartan—type 2 diabetes mellitus	3.54e-05	0.000651	CcSEcCtD
Methysergide—Nausea—Metformin—type 2 diabetes mellitus	3.54e-05	0.000651	CcSEcCtD
Methysergide—Dizziness—Losartan—type 2 diabetes mellitus	3.5e-05	0.000643	CcSEcCtD
Methysergide—Vomiting—Losartan—type 2 diabetes mellitus	3.36e-05	0.000619	CcSEcCtD
Methysergide—Nausea—Irbesartan—type 2 diabetes mellitus	3.34e-05	0.000614	CcSEcCtD
Methysergide—Rash—Losartan—type 2 diabetes mellitus	3.34e-05	0.000613	CcSEcCtD
Methysergide—Dermatitis—Losartan—type 2 diabetes mellitus	3.33e-05	0.000613	CcSEcCtD
Methysergide—Asthenia—Ramipril—type 2 diabetes mellitus	3.26e-05	0.000599	CcSEcCtD
Methysergide—Nausea—Losartan—type 2 diabetes mellitus	3.14e-05	0.000578	CcSEcCtD
Methysergide—Diarrhoea—Ramipril—type 2 diabetes mellitus	3.1e-05	0.000571	CcSEcCtD
Methysergide—Dizziness—Ramipril—type 2 diabetes mellitus	3e-05	0.000552	CcSEcCtD
Methysergide—Vomiting—Ramipril—type 2 diabetes mellitus	2.88e-05	0.00053	CcSEcCtD
Methysergide—Rash—Ramipril—type 2 diabetes mellitus	2.86e-05	0.000526	CcSEcCtD
Methysergide—Dermatitis—Ramipril—type 2 diabetes mellitus	2.86e-05	0.000525	CcSEcCtD
Methysergide—Nausea—Ramipril—type 2 diabetes mellitus	2.7e-05	0.000495	CcSEcCtD
Methysergide—HTR2B—Signaling Pathways—LEP—type 2 diabetes mellitus	2.04e-06	6.19e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—APOE—type 2 diabetes mellitus	2.04e-06	6.19e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—EDN1—type 2 diabetes mellitus	2.04e-06	6.17e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—CCL2—type 2 diabetes mellitus	2.04e-06	6.17e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—EDN1—type 2 diabetes mellitus	2.03e-06	6.14e-05	CbGpPWpGaD
Methysergide—HTR1F—Signaling by GPCR—AKT1—type 2 diabetes mellitus	2.03e-06	6.13e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—APOA1—type 2 diabetes mellitus	2.02e-06	6.12e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—AKT2—type 2 diabetes mellitus	2e-06	6.06e-05	CbGpPWpGaD
Methysergide—HTR2A—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	2e-06	6.05e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—IRS1—type 2 diabetes mellitus	2e-06	6.05e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—IRS1—type 2 diabetes mellitus	2e-06	6.04e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—IRS1—type 2 diabetes mellitus	1.98e-06	6e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—LPL—type 2 diabetes mellitus	1.98e-06	5.99e-05	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.97e-06	5.97e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—LPL—type 2 diabetes mellitus	1.97e-06	5.96e-05	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.95e-06	5.9e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—IRS1—type 2 diabetes mellitus	1.94e-06	5.88e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—ADCY5—type 2 diabetes mellitus	1.94e-06	5.86e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—PRKCB—type 2 diabetes mellitus	1.93e-06	5.84e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—ADCY5—type 2 diabetes mellitus	1.93e-06	5.83e-05	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—SRC—type 2 diabetes mellitus	1.93e-06	5.83e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—INS—type 2 diabetes mellitus	1.91e-06	5.79e-05	CbGpPWpGaD
Methysergide—HTR1E—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.91e-06	5.79e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—INS—type 2 diabetes mellitus	1.91e-06	5.79e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—INS—type 2 diabetes mellitus	1.9e-06	5.75e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	1.89e-06	5.73e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—CCL2—type 2 diabetes mellitus	1.88e-06	5.7e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—CCL2—type 2 diabetes mellitus	1.88e-06	5.69e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—GNB3—type 2 diabetes mellitus	1.88e-06	5.68e-05	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.88e-06	5.68e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—CCL2—type 2 diabetes mellitus	1.87e-06	5.65e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—INS—type 2 diabetes mellitus	1.86e-06	5.63e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	1.86e-06	5.62e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—AVP—type 2 diabetes mellitus	1.85e-06	5.6e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—MMP3—type 2 diabetes mellitus	1.85e-06	5.6e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—IGF1—type 2 diabetes mellitus	1.85e-06	5.6e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—AKT2—type 2 diabetes mellitus	1.85e-06	5.6e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—IGF1—type 2 diabetes mellitus	1.85e-06	5.6e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—AKT2—type 2 diabetes mellitus	1.85e-06	5.59e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	1.85e-06	5.59e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—IGF2—type 2 diabetes mellitus	1.84e-06	5.58e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling by GPCR—EGFR—type 2 diabetes mellitus	1.84e-06	5.57e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling by GPCR—EGFR—type 2 diabetes mellitus	1.84e-06	5.57e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—IGF1—type 2 diabetes mellitus	1.84e-06	5.56e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—AKT2—type 2 diabetes mellitus	1.83e-06	5.56e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	1.83e-06	5.56e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—CCL2—type 2 diabetes mellitus	1.83e-06	5.54e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling by GPCR—EGFR—type 2 diabetes mellitus	1.83e-06	5.53e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—IRS1—type 2 diabetes mellitus	1.82e-06	5.52e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—CCR5—type 2 diabetes mellitus	1.82e-06	5.52e-05	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—SRC—type 2 diabetes mellitus	1.82e-06	5.5e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	1.82e-06	5.5e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—CCR5—type 2 diabetes mellitus	1.81e-06	5.49e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—IGF1—type 2 diabetes mellitus	1.8e-06	5.44e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—AKT2—type 2 diabetes mellitus	1.8e-06	5.44e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—APOB—type 2 diabetes mellitus	1.79e-06	5.42e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling by GPCR—EGFR—type 2 diabetes mellitus	1.79e-06	5.42e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—IGF1R—type 2 diabetes mellitus	1.78e-06	5.39e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—C3—type 2 diabetes mellitus	1.78e-06	5.39e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—C3—type 2 diabetes mellitus	1.77e-06	5.36e-05	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.77e-06	5.36e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—EDN1—type 2 diabetes mellitus	1.76e-06	5.33e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.76e-06	5.32e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.75e-06	5.31e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—INS—type 2 diabetes mellitus	1.75e-06	5.29e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.74e-06	5.28e-05	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.72e-06	5.21e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—CCL2—type 2 diabetes mellitus	1.72e-06	5.2e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—LPL—type 2 diabetes mellitus	1.71e-06	5.17e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.71e-06	5.17e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—HIF1A—type 2 diabetes mellitus	1.7e-06	5.14e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—IRS2—type 2 diabetes mellitus	1.69e-06	5.13e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—AGT—type 2 diabetes mellitus	1.69e-06	5.12e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—HIF1A—type 2 diabetes mellitus	1.69e-06	5.11e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—IGF1—type 2 diabetes mellitus	1.69e-06	5.11e-05	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.69e-06	5.11e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—AKT2—type 2 diabetes mellitus	1.69e-06	5.11e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—IRS2—type 2 diabetes mellitus	1.68e-06	5.1e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—AGT—type 2 diabetes mellitus	1.68e-06	5.1e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling by GPCR—EGFR—type 2 diabetes mellitus	1.68e-06	5.09e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.68e-06	5.08e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.68e-06	5.08e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.68e-06	5.07e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.68e-06	5.07e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—ADCY5—type 2 diabetes mellitus	1.67e-06	5.06e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.66e-06	5.04e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.66e-06	5.04e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—CALM1—type 2 diabetes mellitus	1.66e-06	5.04e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—LEP—type 2 diabetes mellitus	1.66e-06	5.02e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—APOE—type 2 diabetes mellitus	1.66e-06	5.02e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—CALM1—type 2 diabetes mellitus	1.65e-06	5.01e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—APOE—type 2 diabetes mellitus	1.65e-06	4.99e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—LEP—type 2 diabetes mellitus	1.65e-06	4.99e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—APOA1—type 2 diabetes mellitus	1.64e-06	4.96e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.63e-06	4.94e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.63e-06	4.94e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—APOA1—type 2 diabetes mellitus	1.63e-06	4.94e-05	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.62e-06	4.92e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.6e-06	4.86e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	1.6e-06	4.85e-05	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.59e-06	4.82e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—RELA—type 2 diabetes mellitus	1.58e-06	4.78e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—RELA—type 2 diabetes mellitus	1.58e-06	4.78e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—CCR5—type 2 diabetes mellitus	1.57e-06	4.77e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—RELA—type 2 diabetes mellitus	1.57e-06	4.74e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—PRKCB—type 2 diabetes mellitus	1.56e-06	4.73e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—PRKCB—type 2 diabetes mellitus	1.55e-06	4.71e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—C3—type 2 diabetes mellitus	1.54e-06	4.66e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—RELA—type 2 diabetes mellitus	1.53e-06	4.65e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.53e-06	4.64e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.53e-06	4.64e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—IRS1—type 2 diabetes mellitus	1.48e-06	4.48e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—IRS1—type 2 diabetes mellitus	1.47e-06	4.45e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—HIF1A—type 2 diabetes mellitus	1.47e-06	4.44e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—IRS2—type 2 diabetes mellitus	1.46e-06	4.43e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—AGT—type 2 diabetes mellitus	1.46e-06	4.42e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—RELA—type 2 diabetes mellitus	1.44e-06	4.36e-05	CbGpPWpGaD
Methysergide—HTR6—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.44e-06	4.35e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—CALM1—type 2 diabetes mellitus	1.44e-06	4.35e-05	CbGpPWpGaD
Methysergide—HTR7—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.44e-06	4.35e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—LEP—type 2 diabetes mellitus	1.43e-06	4.34e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—APOE—type 2 diabetes mellitus	1.43e-06	4.34e-05	CbGpPWpGaD
Methysergide—HTR1D—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.43e-06	4.32e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.42e-06	4.31e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.42e-06	4.31e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—INS—type 2 diabetes mellitus	1.42e-06	4.29e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—APOA1—type 2 diabetes mellitus	1.42e-06	4.29e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.41e-06	4.28e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.41e-06	4.28e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.41e-06	4.28e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—INS—type 2 diabetes mellitus	1.41e-06	4.27e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.4e-06	4.25e-05	CbGpPWpGaD
Methysergide—HTR1B—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.4e-06	4.23e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—CCL2—type 2 diabetes mellitus	1.39e-06	4.22e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—CCL2—type 2 diabetes mellitus	1.39e-06	4.2e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.38e-06	4.19e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.37e-06	4.16e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—IGF1—type 2 diabetes mellitus	1.37e-06	4.15e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—AKT2—type 2 diabetes mellitus	1.37e-06	4.14e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling by GPCR—EGFR—type 2 diabetes mellitus	1.36e-06	4.13e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—IGF1—type 2 diabetes mellitus	1.36e-06	4.13e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—AKT2—type 2 diabetes mellitus	1.36e-06	4.12e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling by GPCR—EGFR—type 2 diabetes mellitus	1.36e-06	4.1e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—PRKCB—type 2 diabetes mellitus	1.35e-06	4.09e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.35e-06	4.07e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.34e-06	4.07e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.34e-06	4.04e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.33e-06	4.03e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.33e-06	4.03e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.32e-06	4e-05	CbGpPWpGaD
Methysergide—HTR2B—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.31e-06	3.97e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.31e-06	3.96e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.31e-06	3.95e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.3e-06	3.95e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.3e-06	3.94e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.3e-06	3.94e-05	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—IL6—type 2 diabetes mellitus	1.3e-06	3.93e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.3e-06	3.92e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.29e-06	3.92e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.29e-06	3.92e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.29e-06	3.91e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—IRS1—type 2 diabetes mellitus	1.28e-06	3.87e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.27e-06	3.84e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.24e-06	3.76e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.24e-06	3.76e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—SRC—type 2 diabetes mellitus	1.24e-06	3.76e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—SRC—type 2 diabetes mellitus	1.24e-06	3.75e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.24e-06	3.74e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.24e-06	3.74e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—SRC—type 2 diabetes mellitus	1.23e-06	3.73e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.23e-06	3.72e-05	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—IL6—type 2 diabetes mellitus	1.22e-06	3.7e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—INS—type 2 diabetes mellitus	1.22e-06	3.7e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.22e-06	3.68e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.21e-06	3.66e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.21e-06	3.66e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—SRC—type 2 diabetes mellitus	1.21e-06	3.65e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—CCL2—type 2 diabetes mellitus	1.2e-06	3.64e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.2e-06	3.63e-05	CbGpPWpGaD
Methysergide—HTR1F—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.2e-06	3.62e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.19e-06	3.61e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—IGF1—type 2 diabetes mellitus	1.18e-06	3.58e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—AKT2—type 2 diabetes mellitus	1.18e-06	3.58e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—EGFR—type 2 diabetes mellitus	1.18e-06	3.56e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.17e-06	3.56e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—RELA—type 2 diabetes mellitus	1.17e-06	3.54e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—RELA—type 2 diabetes mellitus	1.16e-06	3.52e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—SRC—type 2 diabetes mellitus	1.13e-06	3.43e-05	CbGpPWpGaD
Methysergide—HTR1E—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.13e-06	3.42e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.12e-06	3.4e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.11e-06	3.36e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.11e-06	3.35e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.1e-06	3.34e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.1e-06	3.33e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.09e-06	3.29e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.09e-06	3.29e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.08e-06	3.27e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.08e-06	3.26e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.07e-06	3.25e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.07e-06	3.25e-05	CbGpPWpGaD
Methysergide—HTR1A—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.06e-06	3.22e-05	CbGpPWpGaD
Methysergide—HTR2C—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	1.06e-06	3.2e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.06e-06	3.2e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.05e-06	3.19e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.05e-06	3.18e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.05e-06	3.17e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.04e-06	3.15e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.01e-06	3.07e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—RELA—type 2 diabetes mellitus	1.01e-06	3.06e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—MMP9—type 2 diabetes mellitus	9.96e-07	3.02e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—EGFR—type 2 diabetes mellitus	9.93e-07	3.01e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—MMP9—type 2 diabetes mellitus	9.91e-07	3e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	9.86e-07	2.98e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—NFKB1—type 2 diabetes mellitus	9.81e-07	2.97e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling by GPCR—AKT1—type 2 diabetes mellitus	9.66e-07	2.93e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling by GPCR—AKT1—type 2 diabetes mellitus	9.61e-07	2.91e-05	CbGpPWpGaD
Methysergide—HTR2A—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	9.19e-07	2.78e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—SRC—type 2 diabetes mellitus	9.18e-07	2.78e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—SRC—type 2 diabetes mellitus	9.14e-07	2.77e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—CASP3—type 2 diabetes mellitus	9.11e-07	2.76e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—IL6—type 2 diabetes mellitus	9.05e-07	2.74e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	8.95e-07	2.71e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—VEGFA—type 2 diabetes mellitus	8.9e-07	2.69e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—MMP9—type 2 diabetes mellitus	8.61e-07	2.61e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	8.51e-07	2.58e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—IL6—type 2 diabetes mellitus	8.36e-07	2.53e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—IL6—type 2 diabetes mellitus	8.35e-07	2.53e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling by GPCR—AKT1—type 2 diabetes mellitus	8.35e-07	2.53e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—IL6—type 2 diabetes mellitus	8.29e-07	2.51e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	8.21e-07	2.49e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—TGFB1—type 2 diabetes mellitus	8.17e-07	2.47e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—IL6—type 2 diabetes mellitus	8.12e-07	2.46e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—EGFR—type 2 diabetes mellitus	8.05e-07	2.44e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—EGFR—type 2 diabetes mellitus	8.01e-07	2.42e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—SRC—type 2 diabetes mellitus	7.93e-07	2.4e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	7.73e-07	2.34e-05	CbGpPWpGaD
Methysergide—HTR6—Signaling Pathways—AKT1—type 2 diabetes mellitus	7.71e-07	2.33e-05	CbGpPWpGaD
Methysergide—HTR7—Signaling Pathways—AKT1—type 2 diabetes mellitus	7.7e-07	2.33e-05	CbGpPWpGaD
Methysergide—HTR1D—Signaling Pathways—AKT1—type 2 diabetes mellitus	7.65e-07	2.32e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—IL6—type 2 diabetes mellitus	7.63e-07	2.31e-05	CbGpPWpGaD
Methysergide—HTR1B—Signaling Pathways—AKT1—type 2 diabetes mellitus	7.49e-07	2.27e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	7.09e-07	2.15e-05	CbGpPWpGaD
Methysergide—HTR2B—Signaling Pathways—AKT1—type 2 diabetes mellitus	7.04e-07	2.13e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—EGFR—type 2 diabetes mellitus	6.95e-07	2.11e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—IL6—type 2 diabetes mellitus	6.19e-07	1.87e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—IL6—type 2 diabetes mellitus	6.15e-07	1.86e-05	CbGpPWpGaD
Methysergide—HTR1A—Signaling Pathways—AKT1—type 2 diabetes mellitus	5.71e-07	1.73e-05	CbGpPWpGaD
Methysergide—HTR2C—Signaling Pathways—AKT1—type 2 diabetes mellitus	5.68e-07	1.72e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—IL6—type 2 diabetes mellitus	5.34e-07	1.62e-05	CbGpPWpGaD
Methysergide—HTR2A—Signaling Pathways—AKT1—type 2 diabetes mellitus	4.93e-07	1.49e-05	CbGpPWpGaD
